The Mainz-based company BioNTech that shot to global notoriety amid the COVID-19 pandemic for its work on one of the first mRNA coronavirus vaccines has announced drastic restructuring plans.  The company is winding down its COVID vaccine production entirely, leaving the production to US partner  Pfizer going forward. "In the course of this year we will produce the last doses here in Germany," a company spokeswoman told the Reuters news agency.  What is closing down and how many jobs could be at risk?  Amid the restructuring, the company is closing production centers in Idar-Oberstein, in Marburg, in Singapore in Asia, and another German facility in Tübingen belonging to the CureVac rival company that BioNTech fully took over as of late 2025 after a lengthy acquisition process.…